neoplasm metastasis/hypoxia

A. Early detection of systemic relapses in breast cancer. WP 1. Analysis of primary tumor. Analysis of primary tumor and metastases (Pathology group). In this work package both DNA and RNA from the primary tumors of 125 high-risk (Luminal-B) patients will be analyzed by next-generation sequencing

Surgical resection is the main modality of treatment for many solid tumors. Despite successful tumor resection, some patients develop local recurrence or metastasis, causing morbidities and mortality. In recent years, there is growing interest in the pathophysiology of recurrence or metastasis. It

Non-small cell Lung cancer (NSCLC) is the most frequent type of lung cancer worldwide. Brain metastases (BM) are the most frequent neurological complications related to NSCLC and it is estimated that 20% to 40% of these patients will present them at some point during the progression of their

Soft tissue sarcoma (STS) is a relatively rare type of malignant tumor. For patients with recurrent/distant metastasis/unresectable advanced soft tissue sarcoma, chemotherapy with doxorubicin and ifosfamide is the standard treatment, but the effect is limited. Targeted drugs represented by

Background and preliminary data: Multiple myeloma (MM) is characterized by a clonal expansion of malignant plasma cells in the bone marrow (BM) with a continuous spread of tumour cells in and out of BM. A continuous interaction between BM stromal cells (BMSCs) and MM cells supports proliferation,

Background Breast cancers exhibit a wide scope of morphologic features with demonstrated prognostic significance. These features have the advantage of easily evaluated in routine reporting; thus offering great clinical potential. In our earlier analysis, fibrotic focus (FF) was demonstrated to have

The prognosis for patients with metastatic disease remains poor. The use of immunotherapy in the treatment of cancer is based on the premise that tumors evade the endogenous immune response by being recognized as self, and not non-self. The recent success of immune-modulating agents in patients with

Introduction: Ovarian cancer accounts for 2.5 percent of cancers in women. In Sweden, a total of 694 new cases of ovarian and fallopian tube cancers were reported in 2012. During the period 2005-2009, the relative 1-year survival for all ovarian cancers was 81.8% but 5-year survival was only 44%

A) Study Title: Durvalumab (MEDI4736) as maintenance treatment following chemoradiation for locally advanced unresectable esophageal squamous cell carcinoma (DESC) B) Protocol Number: ESR-17-12757 C) Clinical Phase: 2 D) Study Duration: 36 months E) Investigational Product(s) and Reference Therapy:

The patients who admit the palliative care outpatient clinic of our hospital with the diagnosis of lung cancer (stage 3 and stage 4 non-small cell lung cancer or limited / extensive stage small cell lung cancer) between July 2019-2020 prior to the treatment and the patient who has not yet completed

Background Cancer cell development requires a series of acquired capabilities to grow and spread: 1) self-sufficiency in growth signals, 2) insensitivity to growth inhibition signals, 3) evasion of apoptosis (programmed cell death), 4) limitless replicative potential, 5) sustained angiogenesis and

Liver Transplantation and Limitations of DCD Transplantation: Liver transplantation (LT) is the sole curative therapy for end stage liver disease and has emerged as the treatment of choice for hepatocellular carcinoma. Recent evidence has also demonstrated efficacy in a growing number of

Previous preclinical data and a prospective validated patient cohort have shown that patients with head and neck squamous cell carcinoma, whose tumours are hypoxic after 2 weeks of primary radiochmeotherapy, have a significantly lower chance of locoregional tumour control. The multi-center trial